Stock Research for ONTX

ONTX
Current Price

$1.0700


Latest Update: 2018-02-16 16:00:00

High
$ 1.0700
Low
$ 1.0700
Close
$ 1.0700
Volume
5500
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ONTX Stock Chart & Research Data

The ONTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ONTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ONTX Due diligence Resources & Stock Charts

The ONTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ONTX Detailed Price Forecast - CNN Money CNN View ONTX Detailed Summary - Google Finance
Yahoo View ONTX Detailed Summary - Yahoo! Finance Zacks View ONTX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ONTX Trends & Analysis - Trade-Ideas Barrons View ONTX Major Holders - Barrons
NASDAQ View ONTX Call Transcripts - NASDAQ Seeking View ONTX Breaking News & Analysis - Seeking Alpha
Spotlight View ONTX Annual Report - CompanySpotlight.com OTC Report View ONTX OTC Short Report - OTCShortReport.com
TradeKing View ONTX Fundamentals - TradeKing Charts View ONTX SEC Filings - Bar Chart
WSJ View Historical Prices for ONTX - The WSJ Morningstar View Performance/Total Return for ONTX - Morningstar
MarketWatch View the Analyst Estimates for ONTX - MarketWatch CNBC View the Earnings History for ONTX - CNBC
StockMarketWatch View the ONTX Earnings - StockMarketWatch MacroAxis View ONTX Buy or Sell Recommendations - MacroAxis
Bullish View the ONTX Bullish Patterns - American Bulls Short Pains View ONTX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ONTX Stock Mentions - StockTwits PennyStocks View ONTX Stock Mentions - PennyStockTweets
Twitter View ONTX Stock Mentions - Twitter Invest Hub View ONTX Investment Forum News - Investor Hub
Yahoo View ONTX Stock Mentions - Yahoo! Message Board Seeking Alpha View ONTX Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ONTX - SECform4.com Insider Cow View Insider Transactions for ONTX - Insider Cow
CNBC View ONTX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ONTX - OTC Markets
Yahoo View Insider Transactions for ONTX - Yahoo! Finance NASDAQ View Institutional Holdings for ONTX - NASDAQ


Stock Charts

FinViz View ONTX Stock Insight & Charts - FinViz.com StockCharts View ONTX Investment Charts - StockCharts.com
BarChart View ONTX Stock Overview & Charts - BarChart Trading View View ONTX User Generated Charts - Trading View


Latest Financial News for ONTX

Onconova Therapeutics Announces Closing of $10 Million Underwritten Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Securities
Posted on Monday February 12, 2018

NEWTOWN, Pa., Feb. 12, 2018-- Onconova Therapeutics, Inc., a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary ...


Onconova Therapeutics Announces Pricing of $8.7 Million Underwritten Public Offering
Posted on Thursday February 08, 2018

NEWTOWN, Pa., Feb. 08, 2018-- Onconova Therapeutics, Inc., a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary ...


Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine at American Association for Cancer Epigenetics Research Conference
Posted on Friday February 02, 2018

NEWTOWN, Pa., Feb. 02, 2018-- Onconova Therapeutics, Inc., a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that ...


Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis
Posted on Wednesday January 17, 2018

Independent Data Monitoring Committee recommends continuation of INSPIRE trial with trial expansion per adaptive design based on interim analysis results for overall survival Trial Executive Committee ...


Onconova Therapeutics Announces Closing of $10 Million Underwritten Public ...
GlobeNewswire (press release) - Feb 12, 2018
NEWTOWN, Pa., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a ...

Onconova Therapeutics Announces Pricing of $8.7 Million Underwritten Public ...
GlobeNewswire (press release) - Feb 8, 2018
NEWTOWN, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a ...
Onconova Therapeutics (ONTX) Prices 8.65M Share Common Offering at $1.01/Sh - StreetInsider.com
Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Entry into a Material ... - Market Exclusive

Onconova Therapeutics Inc.
MarketWatch - Apr 4, 2017
Onconova Therapeutics stock surges 18% on positive pre-clinical data for cancer drugs. Apr. 4, 2017 at 9:00 a.m. ET; by Emma Court.

Onconova Therapeutics stock surges 18% on positive pre-clinical data for ...
MarketWatch - Apr 4, 2017
Onconova Therapeutics Inc. ONTX, -3.77% stock surged as much as 18% in premarket trade Tuesday after the company said its two cancer drugs had positive pre-clinical results.

Enter a stock symbol to view the stock details.